Health economic data in reimbursement of new medical technologies: Importance of the socio-economic burden as a decision-making criterion

Frontiers in Pharmacology

Volumn 7, Issue AUG, 2016, Pages

  Iskrov, Georgi ^a,b   Dermendzhiev, Svetlan ^c   Miteva Katrandzhieva, Tsonka ^a,b   Stefanov, Rumen ^a,b  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^b Institute of Rare Diseases   (Bulgaria)

^c MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Burden of disease; Cost effectiveness; Cost of illness; Decision making; Health technology assessment; Rare diseases; Reimbursement; Socio economic burden

Indexed keywords

ARTICLE; BUDGET; CAREGIVER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; PATIENT CARE; PRODUCTIVITY; QUANTITATIVE ANALYSIS; REIMBURSEMENT; RESOURCE ALLOCATION; SOCIOECONOMICS;

EID: 84988640295     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00252     Document Type: Article

References (17)

1. Angelis, A., Kanavos, P., López-Bastida, J., Linertová, R., Nicod, E., Serrano-Aguilar, P., et al. (2015a). Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv. Res. 15:428. doi: 10.1186/s12913-015-1061-3
2. Angelis, A., Tordrup, D., and Kanavos, P. (2015b). Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy 119, 964-79. doi: 10.1016/j.healthpol.2014.12.016
3. Eichler, H. G., Kong, S. X., Gerth, W. C., Mavros, P., and Jönsson, B. (2004). Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7, 518-528. doi: 10.1111/j.1524-4733.2004.75003.x
4. European Union (2009). Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). Official J. Eur. Union C171, 7-10.
5. Iskrov, G., and Stefanov, R. (2014). Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. Orphan Drugs Res. Rev. 4, 1-9. doi: 10.2147/ODRR.S43409
6. Iskrov, G., and Stefanov, R. (2016). Criteria for drug reimbursement decision-making: an emerging public health challenge in Bulgaria. Balkan Med. J. 33, 27-35. doi: 10.5152/balkanmedj.2015.15185
7. Jakovljevic, M., and Getzen, T. E. (2016). Growth of global health spending share in low and middle income countries. Front. Pharmacol. 7:21. doi: 10.3389/fphar.2016.00021
8. Jakovljevic, M., Vukovic, M., Chen, C. C., Antunovic, M., Dragojevic-Simic, V., Velickovic-Radovanovic, R., et al. (2016). Do health reforms impact cost consciousness of health care professionals? Results from a nation-wide survey in the Balkans. Balkan Med. J. 33, 8-17. doi: 10.5152/balkanmedj.2015.15869
9. Jo, C. (2014). Cost-of-illness studies: concepts, scopes, and methods. Clin. Mol. Hepatol. 20, 327-337. doi: 10.3350/cmh.2014.20.4.327
10. López-Bastida, J., Oliva-Moreno, J., Linertová, R., and Serrano-Aguilar, P. (2016). Social/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur. J. Health Econ. 17(Suppl. 1), 1-5. doi: 10.1007/s10198-016-0780-7
11. Mauskopf, J., Chirila, C., Birt, J., Boye, K. S., and Bowman, L. (2013a). Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy 110, 49-59. doi: 10.1016/j.healthpol.2013.01.017
12. Mauskopf, J., Chirila, C., Masaquel, C., Boye, K. S., Bowman, L., Birt, J., et al. (2013b). Relationship between financial impact and coverage of drugs in Australia. Int. J. Technol. Assess. Health Care 29, 92-100. doi: 10.1017/S0266462312000724
13. McCabe, C., Claxton, K., and Culyer, A. J. (2008). The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26, 733-744. doi: 10.2165/00019053-200826090-00004
14. Niezen, M. G., de Bont, A., Busschbach, J. J., Cohen, J. P., and Stolk, E. A. (2009). Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int. J. Technol. Assess. Health Care 25, 49-55. doi: 10.1017/S0266462309090072
15. Panzitta, M., Bruno, G., Giovagnoli, S., Mendicino, F. R., and Ricci, M. (2015). Drug delivery system innovation and health technology assessment: upgrading from clinical to technological assessment. Int. J. Pharm. 495, 1005-1018. doi: 10.1016/j.ijpharm.2015.09.026
16. Rosenberg-Yunger, Z. R., Daar, A. S., Thorsteinsdóttir, H., and Martin, D. K. (2011). Priority setting for orphan drugs: an international comparison. Health Policy 100, 25-34. doi: 10.1016/j.healthpol.2010.09.008
17. Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., et al. (2015). American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J. Clin. Oncol. 33, 2563-2577. doi: 10.1200/JCO.2015.61.6706